Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets
暂无分享,去创建一个
Bin Chen | Atul J. Butte | Hyojung Paik | Marina Sirota | Samuel So | Wei Wei | A. Butte | Bin Chen | M. Sirota | S. So | H. Paik | M. Chua | Wei Wei | Li Ma | Mei-Sze Chua | Li Ma
[1] Atul J. Butte,et al. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma , 2016, Oncotarget.
[2] Marc Hafner,et al. L1000CDS2: LINCS L1000 characteristic direction signatures search engine , 2016, npj Systems Biology and Applications.
[3] Emanuel J. V. Gonçalves,et al. A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.
[4] Ronald J. Moore,et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.
[5] P. Sorger,et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.
[6] Michael L. Gatza,et al. Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.
[7] J. Xu,et al. G protein‐coupled estrogen receptor is involved in modulating colonic motor function via nitric oxide release in C57BL/6 female mice , 2016, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[8] Aravind Subramanian,et al. Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes* , 2016, Molecular & Cellular Proteomics.
[9] A. Butte,et al. Leveraging big data to transform target selection and drug discovery , 2016, Clinical pharmacology and therapeutics.
[10] Chris Sander,et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.
[11] Joel T Dudley,et al. Mapping the effects of drugs on the immune system , 2015, Nature Biotechnology.
[12] Yi Li,et al. Gene expression inference with deep learning , 2015, bioRxiv.
[13] Joshua A. Bittker,et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.
[14] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[15] A. Butte,et al. Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds , 2015, CPT: pharmacometrics & systems pharmacology.
[16] M. Eijken,et al. Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway , 2015, Proceedings of the National Academy of Sciences.
[17] B. Doble,et al. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells , 2015, Clinical Cancer Research.
[18] Bin Chen,et al. Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research , 2015, BMC Medical Genomics.
[19] E. Ruppin,et al. Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia , 2015 .
[20] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[21] S. Baek,et al. RGS2 Suppresses Breast Cancer Cell Growth via a MCPIP1‐Dependent Pathway , 2015, Journal of cellular biochemistry.
[22] Pankaj Agarwal,et al. Systematic evaluation of connectivity map for disease indications , 2014, Genome Medicine.
[23] George W. Sledge,et al. Decade in review—targeted therapy: Successes, toxicities and challenges in solid tumours , 2014, Nature Reviews Clinical Oncology.
[24] P. Bork,et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. , 2014, Cancer research.
[25] D. Vidovic,et al. Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action , 2014, Front. Genet..
[26] Benjamin J. Raphael,et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.
[27] Andrew L. Kung,et al. Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer , 2014, Molecular Cancer Therapeutics.
[28] Gerard J. P. van Westen,et al. Chemical, Target, and Bioactive Properties of Allosteric Modulation , 2014, PLoS Comput. Biol..
[29] Min Huang,et al. Molecularly targeted cancer therapy: some lessons from the past decade. , 2014, Trends in pharmacological sciences.
[30] A. Butte,et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.
[31] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[32] Miran Kim,et al. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.
[33] Mohammad Fallahi-Sichani,et al. Metrics other than potency reveal systematic variation in responses to cancer drugs. , 2013, Nature chemical biology.
[34] Marc Hafner,et al. Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines , 2013, Science Signaling.
[35] Li Li,et al. The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer , 2013, PloS one.
[36] C. Sander,et al. Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.
[37] Tanja Fehm,et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer , 2013, Molecular oncology.
[38] Rui Liu,et al. Pyrvinium targets autophagy addiction to promote cancer cell death , 2013, Cell Death and Disease.
[39] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[40] Bas J Blaauboer,et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. , 2013, Journal of proteomics.
[41] 鄒佩玲,et al. 美國癌症基因體圖譜計畫TCGA(The Cancer Genome Atlas)簡介 , 2013 .
[42] Pankaj Agarwal,et al. Evaluation of Analytical Methods for Connectivity Map Data , 2012, Pacific Symposium on Biocomputing.
[43] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[44] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[45] P. Workman,et al. Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.
[46] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[47] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[48] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.
[49] Valerie Speirs,et al. Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.
[50] A. Ruiz i Altaba,et al. BMP signaling promotes the growth of primary human colon carcinomas in vivo. , 2010, Journal of molecular cell biology.
[51] Bruce J. Melancon,et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. , 2010, Nature chemical biology.
[52] R. Tagliaferri,et al. Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.
[53] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[54] P. Sunnerhagen,et al. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation , 2009, Radiation oncology.
[55] Timothy H. Davis,et al. Pyrvinium Targets the Unfolded Protein Response to Hypoglycemia and Its Anti-Tumor Activity Is Enhanced by Combination Therapy , 2008, PloS one.
[56] G. Moreno-Bueno,et al. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis , 2007, Oncogene.
[57] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[58] M. Lacroix,et al. Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.
[59] Ming-Yao Wu,et al. Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. , 2002, World journal of gastroenterology.
[60] P. Polakis,et al. Activation of the Wnt Pathway Interferes with Serum Response Element-driven Transcription of Immediate Early Genes* , 2002, The Journal of Biological Chemistry.
[61] I. So,et al. FCCP depolarizes plasma membrane potential by activating proton and Na+ currents in bovine aortic endothelial cells , 2001, Pflügers Archiv.
[62] S. Bisti,et al. Effect of blocking the Na+/K+ ATPase on Ca2+ extrusion and light adaptation in mammalian retinal rods. , 1995, Biophysical journal.
[63] K. Johnson. An Update. , 1984, Journal of food protection.